Hikma Pharmaceuticals PLC (HIK.L) Quote| Reuters.com
Edition:
United States

Hikma Pharmaceuticals PLC (HIK.L)

HIK.L on London Stock Exchange

2,530.00GBp
1 Jul 2016
Change (% chg)

65.00p (+2.64%)
Prev Close
2,465.00p
Open
2,481.00p
Day's High
2,535.00p
Day's Low
2,466.00p
Volume
574,687
Avg. Vol
724,368
52-wk High
2,535.00p
52-wk Low
1,575.00p

HIK.L

Chart for HIK.L

About

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The... (more)

Overall

Beta: 1.37
Market Cap(Mil.): £6,090.67
Shares Outstanding(Mil.): 239.92
Dividend: 14.60
Yield (%): --

Financials

  HIK.L Industry Sector
P/E (TTM): 26.84 35.27 36.15
EPS (TTM): 0.95 -- --
ROI: 15.03 15.09 14.31
ROE: 19.89 16.14 15.51

Hikma seeks dismissal of Takeda's bid to block gout drug sales

Hikma Pharmaceuticals PLC is asking a federal appeals court to reject a bid by rival Takeda Pharmaceutical Co to halt sales of Hikma's gout drug Mitigare, arguing that the challenge is moot after Hikma won a separate patent case last month.

Jun 09 2016

Hikma wins dismissal of Takeda patent lawsuit over gout drug

A federal court has cleared the way for Hikma Pharmaceuticals Plc to continue selling a drug with the same active chemical as Takeda Pharmaceutical Co's gout drug Colcrys, dismissing a patent lawsuit Takeda filed in an effort to keep the drug off the market.

May 20 2016

BRIEF-Hikma Pharma says investors approve directors' pay

* 88.97 pct votes cast at AGM in favour of approval of 2015 remuneration implementation, 11.03 percent against

May 12 2016

BRIEF-Hikma Pharma reiterates guidance for 2016

* Continue to expect full year group revenue to be in range of $2.0 billion to $2.1 billion

May 12 2016

BRIEF-Hikma Pharmaceuticals keeps 2016 generic revenue forecast

* Group revenue expected to be in range of $2.0 billion to $2.1 billion in 2016

Mar 16 2016

BRIEF-Hikma says Roxane acquisition close

* Co is pleased to announce that Roxane acquisition closed today, following satisfaction of all necessary conditions. Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +91 80 6749 1136)

Feb 29 2016

Deals of the day- Mergers and acquisitions

Feb 26 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:

Feb 26 2016

U.S. sets conditions for Hikma's takeover of Boehringer's Roxane

WASHINGTON Drug manufacturer Hikma Pharmaceuticals Plc will sell the rights and assets of two generic drugs and relinquish its U.S. marketing rights to a third generic drug in order to settle Federal Trade Commission charges that Hikma’s proposed $2 billion acquisition of Roxane would likely be anticompetitive, the FTC said on Friday.

Feb 26 2016

U.S. sets conditions for Hikma's takeover of Boehringer's Roxane

WASHINGTON, Feb 26 Drug manufacturer Hikma Pharmaceuticals Plc will sell the rights and assets of two generic drugs and relinquish its U.S. marketing rights to a third generic drug in order to settle Federal Trade Commission charges that Hikma's proposed $2 billion acquisition of Roxane would likely be anticompetitive, the FTC said on Friday.

Feb 26 2016

Hikma cuts offer for Boehringer's U.S. generic drug unit

Hikma Pharmaceuticals Plc almost halved the cash portion of its offer for Boehringer Ingelheim's U.S. generic drugs business on Wednesday, after further due diligence revealed that the unit's 2015 revenue would be lower than expected.

Feb 10 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : MacroRisk Analytics/EconomicInvestor
$25.00
Provider : Sadif Analytics Prime
$25.00
Provider : Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.